PENPenumbra, Inc.

$323.27

$225.5452 weeks$359.40

Price

$323.27+34%1Y

1M+1.7%1Y+34%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value33

Quality84

Momentum53

Growth65

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We sell our products to healthcare providers primarily through our direct sales organization in the United States, most of Europe, Canada, Australia and Singapore, as well as through distributors in select international markets. We generated revenue of $1,403.7 million, $1,194.6 million and $1,058.5 million for the years ended December 31, 2025, 2024 and 2023, respectively. This represents an annual increase of 17.5% and 12.9%, respectively.

In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR

P/E (TTM)74.5

Market Cap$12.48B

1Y Return+34%

5Y Return+22%

Business segments

Q1 2026 · $374.8M

The company’s own SEC segment disclosure.

Thrombectomy$253.9M68%
Embolization And Access$120.8M32%

Penumbra, Inc. (PEN) reported revenue of $375M in Q1 2026 (quarter ended March 31, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $33M (8.7% of revenue). For the full year FY2025, revenue was $1.40B (+17% year on year) and net income $178M. Its largest product in 2026-Q1 was Thrombectomy at $254M, 68% of the disclosed total, just ahead of Embolization And Access at 32%.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Medical Devices

Ranks #19 of 35 by Smart Score